CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 5 of 5 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT04927702 Org: User:

Start: 07/19/21 End: 08/01/24 Due: 08/01/25

Phase: N/A Priority: Normal

NCT ID: NCT04918784 Org: User:

Start: 05/05/21 End: 12/01/22 Due: 12/01/23

Phase: N/A Priority: Normal

NCT ID: NCT06578650 Org: User:

Start: 10/31/24 End: 05/31/27 Due: 05/31/28

Phase: N/A Priority: Normal

NCT ID: NCT03312595 Org: User:

Start: 09/14/17 End: 07/30/18 Due: 07/30/19

Phase: N/A Priority: Normal

NCT ID: NCT04829331 Org: User:

Start: 04/09/21 End: 01/01/22 Due: 01/01/23

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)	NCT04927702	Acera Surgical, Inc.	user2@example.com	None	2021-07-19	2024-08-01	2025-08-01	-	-	2025-07-14
Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers	NCT04918784	Acera Surgical, Inc.	user2@example.com	None	2021-05-05	2022-12-01	2023-12-01	-	-	2025-07-14
A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms	NCT06578650	Acera Surgical, Inc.	user2@example.com	None	2024-10-31	2027-05-31	2028-05-31	-	-	2025-07-14
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)	NCT03312595	Acera Surgical, Inc.	user2@example.com	None	2017-09-14	2018-07-30	2019-07-30	-	-	2025-07-14
Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site	NCT04829331	Acera Surgical, Inc.	user2@example.com	None	2021-04-09	2022-01-01	2023-01-01	-	-	2025-07-14